fluorobenzenes has been researched along with Metabolic Syndrome in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (61.54) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balligand, JL; Beauloye, C; Hamelet, J; Herijgers, P; Hermida, N; Hilfiker-Kleiner, D; Horman, S; Markl, A; Noppe, G; Van Assche, T; van Bilsen, M; Vanderper, A | 1 |
| Black, CA; Fleming, JW; Malinowski, SS; Miller, KH; Riche, DM; Wofford, MR | 1 |
| Bostan, C; Kaya, A; Ozkan, AA; Uzunhasan, I; Yigit, Z; Yildiz, A | 1 |
| Ayan, S; Dundar, G; Erden, Y; Gokce, G; Gultekin, EY; Korgalı, E; Yildirim, S | 1 |
| Athyros, VG; Giouleme, O; Karagiannis, A; Kargiotis, K; Katsiki, E; Katsiki, N; Mikhailidis, DP; Patsiaoura, K | 1 |
| Barrett, PH; Chan, DC; Meikle, PJ; Ng, TW; Ooi, EM; Watts, GF; Weir, JM | 1 |
| Barrett, PH; Chan, DC; Meikle, PJ; Ng, TW; Ooi, EM; Watts, GF | 1 |
| Barrett, PH; Chan, DC; Chen, MM; Nestel, PJ; Ooi, EM; Sviridov, D; Watts, GF | 1 |
| Hsia, J; Otvos, JD; Rosenson, RS | 1 |
| Cathey, BL; Moukdar, F; Prasad, RY; Wilkinson, L; Wingard, CJ | 1 |
| Abate, N; Ballantyne, CM; Catapano, AL; Davidson, MH; Polis, AB; Smugar, SS; Tershakovec, AM | 1 |
| Amsterdam, EA; Kappagoda, CT | 1 |
| Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT | 1 |
| Hayashi, J; Hayashi, S; Maeda, S; Ohnishi, H; Sawayama, Y | 1 |
| Chae, JK; Choi, JY; Hong, TJ; Jeong, MH; Kim, DS; Kim, KY; Kim, YJ; Kim, YN; Oh, SK; Park, JS; Seong, IW | 1 |
| Ferdinand, KC | 1 |
| Agatston, A; Blaha, MJ; Blankstein, R; Blumenthal, RS; Budoff, MJ; Criqui, MH; Cushman, M; Lakoski, S; Nasir, K; O'Leary, DH; Rivera, JJ; Szklo, M | 1 |
| Averna, M; Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Missault, L; Shah, A; Taggart, W; Vaverkova, H; Viigimaa, M | 1 |
| Agouridis, AP; Bairaktari, ET; Elisaf, MS; Kostapanos, MS; Kostara, C; Mikhailidis, DP; Tselepis, AD; Tsimihodimos, V | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J | 1 |
| Bernal-Rosales, LP; Cervantes, JL; Gonzalez, JG; Marin, JA; Martinez, G; Ocampo, R; Polanco, A; Rodriguez-Briones, I; Sanchez-Mijangos, H; Talavera, JO | 1 |
| Ballantyne, CM; Blasetto, JW; Paoletti, R; Southworth, H; Stein, EA | 1 |
| Ridker, PM | 2 |
| Avogaro, A | 1 |
| Rosenson, RS | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Barter, P; Kallend, D; Schuster, H; Stender, S; Watkins, C | 1 |
| Adeli, K; Cheung, RC; Chong, T; Federico, L; Naples, M; Smith, GJ; Taylor, D | 1 |
| Ballantyne, CM; Murin, J; Rose, H; Sarti, C; Stalenhoef, AF; Tonstad, S; Wilpshaar, W | 1 |
| Knopp, RH; Paramsothy, P | 1 |
| De Hert, M; Hanssens, L; Kalnicka, D; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
| Bellomo, A; Ettorre, E; Mancinella, M; Marigliano, V; Troisi, G | 1 |
| Barrett, PH; Chan, DC; Nestel, PJ; Ooi, EM; Watts, GF | 1 |
| Barrett, PH; Hoang, A; Nestel, P; Ooi, E; Sviridov, D; Watts, G | 1 |
| Barrett, PH; Hoang, A; Nestel, PJ; Ooi, EM; Sviridov, D; Watts, GF | 1 |
| Coppey, LJ; Davidson, EP; Kleinschmidt, TL; Lund, DD; Oltman, CL; Yorek, MA | 2 |
| Jukema, JW; Liem, AH; van de Woestijne, AP; Visseren, FL; Zwinderman, AH | 1 |
5 review(s) available for fluorobenzenes and Metabolic Syndrome
| Article | Year |
|---|---|
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2003 |
High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention.
Topics: Aged; C-Reactive Protein; Female; Fluorobenzenes; Humans; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides | 2003 |
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides | 2003 |
[Diabetes and multimetabolic syndrome].
Topics: Diabetes Mellitus; Fluorobenzenes; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin Resistance; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2003 |
Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Topics: Drug Interactions; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2003 |
20 trial(s) available for fluorobenzenes and Metabolic Syndrome
| Article | Year |
|---|---|
Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report.
Topics: Adult; Biopsy; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver Function Tests; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2014 |
Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome.
Topics: Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Phospholipids; Pyrimidines; Rosuvastatin Calcium; Sphingolipids; Sulfonamides | 2014 |
Association of Plasma Ceramides and Sphingomyelin With VLDL apoB-100 Fractional Catabolic Rate Before and After Rosuvastatin Treatment.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-100; Ceramides; Fluorobenzenes; Humans; Kinetics; Lipid Metabolism; Lipoproteins, VLDL; Male; Metabolic Syndrome; Metabolism; Middle Aged; Obesity, Abdominal; Pyrimidines; Rosuvastatin Calcium; Sphingomyelins; Sulfonamides | 2015 |
Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome.
Topics: Apolipoprotein C-III; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leucine; Lipoproteins, VLDL; Male; Metabolic Syndrome; Placebos; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Atorvastatin; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged; Placebos; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides; White People | 2009 |
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Double-Blind Method; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2009 |
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention
Topics: Age Factors; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endpoint Determination; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Myocardial Infarction; Myocardial Revascularization; Primary Prevention; Pyrimidines; Racial Groups; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2009 |
Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Cholesterol; Clinical Chemistry Tests; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pravastatin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2010 |
Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia.
Topics: Atorvastatin; Blood Glucose; Cholesterol, LDL; Female; Fluorobenzenes; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperglycemia; Insulin; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2010 |
Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Drug Combinations; Drug Substitution; Europe; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Lipids; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Odds Ratio; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.
Topics: Apolipoproteins; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Male; Medication Adherence; Metabolic Syndrome; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2012 |
The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Blood Glucose; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Fasting; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
A double-blind, double-dummy, randomized, placebo-controlled trial to evaluate the effect of statin therapy on triglyceride levels in Mexican hypertriglyceridemic patients.
Topics: Apolipoprotein A-I; Apolipoproteins B; Cardiovascular Diseases; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Lipoproteins, HDL; Lipoproteins, LDL; Male; Metabolic Syndrome; Mexico; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2013 |
Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Europe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Triglycerides | 2003 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Atorvastatin; C-Reactive Protein; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2005 |
Treatment of hypercholesterolemia in patients with metabolic syndrome: how do different statins compare?
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Dose-dependent effect of rosuvastatin on apolipoprotein B-100 kinetics in the metabolic syndrome.
Topics: Adult; Apolipoprotein B-100; Apolipoprotein C-III; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Cross-Over Studies; Dose-Response Relationship, Drug; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin.
Topics: Adult; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2008 |
Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Particle Size; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
15 other study(ies) available for fluorobenzenes and Metabolic Syndrome
| Article | Year |
|---|---|
HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Topics: Actins; AMP-Activated Protein Kinases; Animals; Cells, Cultured; Collagen Type I; Diastole; Disease Models, Animal; Enzyme Activation; Fibroblasts; Fibrosis; Fluorobenzenes; Heart Diseases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Procollagen; Pyrimidines; Rats; Receptors, LDL; Recovery of Function; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Time Factors; Transfection; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling | 2013 |
Resistant nonalcoholic fatty liver disease amelioration with rosuvastatin and pioglitazone combination therapy in a patient with metabolic syndrome.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Drug Resistance; Drug Therapy, Combination; Dyslipidemias; Fatty Liver; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Thiazolidinediones | 2014 |
Beneficial effects of rosuvastatin treatment in patients with metabolic syndrome.
Topics: Adult; Aged; Biomarkers; C-Reactive Protein; Female; Fibrinogen; Fluorobenzenes; Glycated Hemoglobin; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Metabolic Syndrome; Middle Aged; Oxidative Stress; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome | 2015 |
In-vitro effects of PDE5 inhibitor and statin treatment on the contractile responses of experimental MetS rabbit's cavernous smooth muscle.
Topics: Animals; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Metabolic Syndrome; Muscle Contraction; Muscle Relaxation; Myocytes, Smooth Muscle; Penis; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sildenafil Citrate; Sulfonamides; Sulfones | 2014 |
Reversal of voltage-dependent erectile responses in the Zucker obese-diabetic rat by rosuvastatin-altered RhoA/Rho-kinase signaling.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; Diabetes Mellitus, Experimental; Electric Stimulation; Enzyme Inhibitors; Erectile Dysfunction; Fluorobenzenes; Impotence, Vasculogenic; Intracellular Signaling Peptides and Proteins; Male; Metabolic Syndrome; Nitric Oxide; Obesity; Phosphodiesterase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Zucker; rho-Associated Kinases; Rosuvastatin Calcium; Sulfonamides | 2009 |
Another look at the results of the JUPITER trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus; Female; Fluorobenzenes; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2009 |
Achieving treatment goals in low-risk, asymptomatic patients.
Topics: Albuminuria; Antihypertensive Agents; Biomarkers; Black or African American; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluorobenzenes; Health Status Indicators; Humans; Hypolipidemic Agents; Metabolic Syndrome; Middle Aged; Obesity; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Sulfonamides; United States | 2010 |
Association between obesity, high-sensitivity C-reactive protein ≥2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis.
Topics: Adult; Aged; Atherosclerosis; Body Mass Index; C-Reactive Protein; Calcium; Cardiovascular Diseases; Carotid Arteries; Clinical Trials as Topic; Cross-Sectional Studies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Obesity; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tunica Intima; Tunica Media; Waist Circumference | 2011 |
Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Triglycerides | 2005 |
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Topics: Animals; Apolipoproteins B; Cells, Cultured; Chromatography, Gel; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dyslipidemias; Electrophoresis, Polyacrylamide Gel; Fluorobenzenes; Hepatocytes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Liver; Male; Mesocricetus; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Cardiovascular Diseases; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Middle Aged; Psychotic Disorders; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Schizophrenia; Sulfonamides; Treatment Outcome | 2006 |
Diabetes and metabolic syndrome (MS).
Topics: Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Metabolic Syndrome; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2007 |
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Coronary Vessels; Diabetes Mellitus, Type 2; Enalapril; Endothelium, Vascular; Fatty Acids; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenteric Arteries; Metabolic Syndrome; Oxidative Stress; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2008 |
Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin.
Topics: Acetylcholine; Angiotensin-Converting Enzyme Inhibitors; Animals; Arterioles; Cardiovascular System; Disease Models, Animal; Enalapril; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Motor Neurons; Neural Conduction; Neurons, Afferent; Nociceptors; Obesity; Peripheral Nerves; Pyrimidines; Rats; Rats, Zucker; Rosuvastatin Calcium; Sciatic Nerve; Sulfonamides; Superoxides; Tyrosine; Vasodilator Agents | 2008 |
Determinants of CRP level in statin-treated patients.
Topics: Atorvastatin; Blood Pressure; C-Reactive Protein; Enzyme Inhibitors; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Logistic Models; Male; Metabolic Syndrome; Middle Aged; Pilot Projects; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; Sulfonamides | 2008 |